Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Dr Reddys Laboratories, says Sukhani

      One can buy Dr Reddys Laboratories and if it crosses Friday‘s highs then go long in it, says Sudarshan Sukhani of s2analytics.com.

    • ICICI Direct's F&O strategy for next week

      The Call and Put writing both that has brought down the volatility and this is where there maybe some consolidation left in the market till expiry.

    • Dr Reddys Labs can cross Rs 2100: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Brokers is of the view that Dr Reddys Laboratories can cross Rs 2100 and can see a move towards Rs 2150 in this settlement.

    • Dr Reddy's Lab top pick in pharma: IIFL Capital

      Bino Pathiparampil of IIFL Capital told CNBC-TV18 that there has been a major rally in the sector over the last couple of years. Thus, many of the stocks went up 20 percent in the last couple of months itself.

    • Dr Reddys Labs to see deep correction: Sukhani

      Sudarshan Sukhani of s2analytics.com feels Dr Reddys Laboratories is heading for deep correction. "It has broken down from a clear trading range on the downside," he reasoned.

    • Lupin, Sun Pharma, Dr Reddys Labs safe bets: Tater

      Aashish Tater, Head of Research, Fortunewizard.com is of the view that Lupin, Sun Pharmaceutical Industries and Dr Reddys Laboratories are safe bets. "We are still making a positive view for Lupin. It is just that the technical snapshot suggests that there has been some gap around Rs 766 and Rs 804 zone, he added.

    • SPARC can give good returns: Aashish Tater

      Aashish Tater, Head of Research, Fortunewizard.com feels that there is lot of money that can be made in Sun Pharma Advance Research Company.

    • Hold Dr Reddys Laboratories: Prakash Diwan

      One can hold Dr Reddys Laboratories, says Prakash Diwan, Chief Portfolio Strategist of Prakash Diwan's Wealth Circle, ECR.

    • Buy Dr Reddys Labs 2000 Call: VK Sharma

      VK Sharma of HDFC Securities said one could consider buying Dr Reddys Labs 2000 Call, with a stop loss of Rs 40.

    • Buy Dr Reddys Laboratories, says Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that, one should buy Dr Reddys Laboratories.

    • Dr Reddys Labs may see 5-7% upside: Malkan

      Dr Reddys Labs may see 5-7% upside, says Vishal B Malkan, malkansview.com.

    • Super Six stocks you can bet on April 22

      On CNBC-TV18's show Super Six, market gurus Rajesh Jain, Religare Securities, Vikrant Jadeja, vibranttrades.com and Vishal Malkan, malkansview.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buying opportunities seen in HPCL, Dr Reddys Labs: Sukhani

      Buying opportunities is seen in HPCL and Dr Reddys Labs at current levels, says Sudarshan Sukhani, s2analytics.com.

    • Buy Dr Reddys Labs around Rs 1900: Murlidharan

      Manoj Murlidharan, IIFL advises to buy Dr Reddys Labs around Rs 1900 with a stop loss of Rs 1884.

    • Sukhani upbeat on Dr Reddys Lab

      Sudarshan Sukhani of s2analytics.com is upbeat on Dr Reddys Lab.

    • See lot of speculative upside in ADAG stocks: PN Vijay

      In an interview to CNBC-TV18, portfolio manager PN Vijay spoke about various stocks, sector and all that is making news in the market right now.

    • Check out: Top chart picks by market experts

      In an interview to CNBC-TV18, Sudarshan Sukhani of s2analytics.com, SP Tulsian of sptulsian.com and Hemant Thukral, Aditya Birla Money give top pick for the day.

    • Ranbaxy Labs, Dr Reddy Labs good bets: Vora

      Ranbaxy Labs and Dr Reddy Labs are good bets in pharma space, says Amisha Vora, Prabhudas Lilladher.

    • 5 stock ideas to liven up your trade

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, manasjaiswal.com, Manav Chopra, Nirmal Bang and Rakesh Gandhi, FRR share, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Prefer Dr Reddy, Cipla over Shasun Pharma: Sukhani

      Sudarshan Sukhani, s2analytics.com advises to switch from Shasun Pharmaceuticals to Dr Reddy and Cipla.

    • Sukhani upbeat on Cipla, Dr Reddys Labs

      Sudarshan Sukhani, s2analytics.com is upbeat on Cipla and Dr Reddys Labs.

    • Bull's Eye: Buy PTC, YES Bank, Cairn, Tata Global

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • HUL, Dr Reddys Laboratories likely to outperform: Sukhani

      Sudarshan Sukhani, s2analytics.com is of the view that HUL, Dr Reddys Laboratories likely to outperform.

    • Buy Dr Reddys Laboratories, says Sukhani

      One can take positional trade in Dr Reddys Laboratories. It is also a trade that one wants to do intraday for the day because any small move in the Nifty could see big gains in this one, says Sudarshan Sukhani of s2analytics.com.

    • Short Dr Reddys Laboratories: Sukhani

      Short Dr Reddys Laboratories, says Sudarshan Sukhani of s2analytics.com.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347